Should I buy or sell Celadon Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CEL shares. View CEL analyst ratings or view top-rated stocks .

What is Celadon Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 12-month price targets for Celadon Pharmaceuticals' shares. Their CEL share price targets range from GBX 210 to GBX 235. On average, they expect the company's share price to reach GBX 222.50 in the next year. This suggests a possible upside of 93.5% from the stock's current price. View analysts price targets for CEL or view top-rated stocks among Wall Street analysts .

How have CEL shares performed in 2024?

Celadon Pharmaceuticals' stock was trading at GBX 115 at the beginning of the year. Since then, CEL stock has increased by 0.0% and is now trading at GBX 115. View the best growth stocks for 2024 here .

How do I buy shares of Celadon Pharmaceuticals?

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free CEL Stock Alerts

GBX 115

-2.50 (-2.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: 110
▼
120
50-Day Range: 78.50
▼
120
52-Week Range: 73.44
▼
180

Volume: 110,673 shs
Average Volume: 40,114 shs
Market Capitalization: £73.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: GBX 222.50

Stock Analysis Analyst Forecasts Chart Competitors Headlines

Get Celadon Pharmaceuticals alerts:

Ad Banyan Hill Publishing

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

About Celadon Pharmaceuticals Stock (LON:CEL)

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

CEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CEL Stock News Headlines

February 28, 2024 | morningstar.com

Celadon Pharmaceuticals PLC CEL

December 14, 2023 | lse.co.uk

Celadon announces start of cannabis supply for two UK companies

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

December 12, 2023 | lse.co.uk

TRADING UPDATES: Celadon Pharma raises GBP2.0 million via placing

December 4, 2023 | msn.com

UK's First Medical Marijuana Clinical Trial Gets Underway: National Health Service Remains Cautious

November 16, 2023 | lse.co.uk

Celadon shares rise on supply contract worth up to GBP26 million

October 13, 2023 | marketwatch.com

Celadon Pharmaceuticals to Raise GBP1 Mln via Discounted Placing, Subscription

October 1, 2023 | finance.yahoo.com

Celadon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

September 28, 2023 | lse.co.uk

Celadon Pharmaceuticals interim loss narrows; optimistic for future

September 5, 2023 | lse.co.uk

Celadon shares rise on second UK contract win for cannabis product

September 5, 2023 | marketwatch.com

Celadon Pharmaceuticals Enters New Contract Worth Up to GBP1.2 Mln in Revenue

August 22, 2023 | finance.yahoo.com

Owning 61% in Celadon Pharmaceuticals Plc (LON:CEL) means that insiders are heavily invested in the company's future

August 1, 2023 | ca.finance.yahoo.com

CEL.L - Celadon Pharmaceuticals Plc

August 1, 2023 | lse.co.uk

Celadon receives approval for 5,000 patient clinical cannabis trial

June 9, 2023 | finance.yahoo.com

Investors’ Chronicle: Oxford Metrics, N Brown, Celadon Pharmaceuticals

June 5, 2023 | lse.co.uk

Celadon Pharmaceuticals loss widens; confident amid three-year deal

May 30, 2023 | lse.co.uk

Celadon secures GBP7 million credit facility as product demand grows

May 30, 2023 | marketwatch.com

Celadon Pharmaceuticals Shares Rise on New GBP7 Mln Line of Credit

May 24, 2023 | lse.co.uk

Celadon signs commercial cannabis supply agreement with UK firm

May 24, 2023 | lse.co.uk

CORRECT: Celadon signs commercial cannabis supply agreement in UK

April 20, 2023 | finance.yahoo.com

C15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech Platform

March 15, 2023 | finance.yahoo.com

James Short Celadon Pharmaceuticals Plc's (LON:CEL) CEO is the most bullish insider, and their stock value gained 162%last week

March 14, 2023 | thetimes.co.uk

Fresh permit for cannabis lifts Celadon

March 14, 2023 | marketwatch.com

Celadon Pharmaceuticals Shares Jump as Sale of Pharmaceutical Cannabis Product Granted

January 16, 2023 | thetimes.co.uk

Celadon wins right to cultivate and make medicinal cannabis oil

January 16, 2023 | markets.businessinsider.com

Celadon Pharma's Midlands UK Facility Gets GMP Registration By MHRA; Stock Up

See More Headlines

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: LON:CEL
CUSIP: N/A
CIK: N/A
Web: www.celadonpharma.co.uk
Phone: 44 20 3150 0252
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 222.50
High Stock Price Target: GBX 235
Low Stock Price Target: GBX 210
Potential Upside/Downside: +85.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX (0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-7,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -122.33%
Return on Assets: -35.60%

Debt

Debt-to-Equity Ratio: 153.26
Current Ratio: 1.86
Quick Ratio: 6.97

Sales & Book Value

Annual Sales: £11,258.00
Price / Sales: 6,844.20
Cash Flow: GBX 39.31 per share
Price / Cash Flow: 3.05
Book Value: GBX 5 per share
Price / Book: 24.00

Miscellaneous

Outstanding Shares: 64,210,000
Free Float: N/A
Market Cap: £77.05 million
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. James Gareth Short (Age 56)
CEO & Executive Director
Comp: $246.15k
Mr. Jonathan Paul Turner (Age 46)
CFO & Director
Ms. Kerin Williams (Age 54)
Company Secretary

Key Competitors

View All Competitors

CEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Celadon Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CEL shares.
View CEL analyst ratings or view top-rated stocks.
What is Celadon Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 12-month price targets for Celadon Pharmaceuticals' shares. Their CEL share price targets range from GBX 210 to GBX 235. On average, they expect the company's share price to reach GBX 222.50 in the next year. This suggests a possible upside of 93.5% from the stock's current price.
View analysts price targets for CEL or view top-rated stocks among Wall Street analysts.
How have CEL shares performed in 2024?: Celadon Pharmaceuticals' stock was trading at GBX 115 at the beginning of the year. Since then, CEL stock has increased by 0.0% and is now trading at GBX 115.
View the best growth stocks for 2024 here.
How do I buy shares of Celadon Pharmaceuticals?: Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:CEL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial